To conclude, here we show, for the first time, that intratumoral, but not circulating CD33+HLA-DR−CD16−CD11b+ MDSCs bare suppressive capabilities and are associated with decreased rate of pathological response to nCRT in patients with locally advanced rectal cancer. The gene discussed is CD33; the disease is rectal cancer.